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Abstract
Producing stable nanocrystals confined to porous excipient media is a desirable way to increase 
the dissolution rate and improve the bioavailability of poorly water soluble pharmaceuticals. The 
poorly soluble pharmaceutical fenofibrate was crystallized in controlled pore glass (CPG) of 10 
different pore sizes between 12 nm and 300 nm. High drug loadings of greater than 20 wt% were 
achieved across all pore sizes greater than 20 nm. Nanocrystalline fenofibrate was formed in pore 
sizes greater than 20 nm and showed characteristic melting point depressions following a Gibbs-
Thomson relationship as well as enhanced dissolution rates. Solid-state Nuclear Magnetic 
Resonance (NMR) was employed to characterize the crystallinity of the confined molecules. 
These results help to advance the fundamental understanding of nanocrystallization in confined 
pores.
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Pharmaceutical nanocrystals have been targeted as a solution for improving the 
bioavailability of poorly water soluble pharmaceuticals [1] [2]. Nanocrystals have an 
increased surface area to volume ratio compared to their bulk crystal counterparts and can 
increase dissolution rate according to the Noyes-Whitney equation [3] and enhance 
permeability [4]. It has also been shown that the solubility increases with decreasing particle 
size below a cut-off size of 1-2 μm [5]. It is desirable to produce nanocrystals directly 
without resorting to other processing steps such as milling to achieve nanocrystal size while 
also controlling the polymorphism of the crystal [6].
Several bottom-up methods to produce nanocrystals of a given size in reproducible 
polymorphs exist. These include the “hydrosol” method [5], freeze-drying [6], supercritical 
fluid methods [7] [8], cryogenic spray processes [9], and evaporative precipitation into 
aqueous solution [10] [11]. These processes often produce amorphous material or an 
undesired polymorphic form. In addition, control of size distribution and can be difficult to 
scale up. They can be plagued with low production rates and typically do not achieve 
particle sizes below 100 nm [1] [6] [12] [13].
Alternative approaches for producing stable pharmaceutical nanocrystals employ the 
bottom-up approach of conducting the crystallization in confinement. Ordered mesoporous 
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silica [14] [15] [16] [17] [18] [19] [20] [21], controlled pore glass (CPG) [22] [23], porous 
polycyclohexylethylene and polystyrene (p-PCHE) [22] [24], nanostructured lipid carriers 
[25], fumed silica [26], and solutions of active pharmaceutical ingredients (APIs) in 
electrospun materials [27] have all been used to confine APIs to small volumes [28]. 
Confining crystals to porous matrices of known size addresses the issue of particle size 
distributions, and has been proposed to lead to higher polymorph control through regulation 
of nucleation [29] as well as the stabilization of otherwise metastable polymorphs [30]. 
Producing confined nanocrystals has also been proposed as a way to better understand 
fundamentals of polymorph formation, due to the unique surface energy effects of the 
confined systems [31].
Ha et al. [22] have found a Gibbs-Thomson like relationship between melting point 
depression and crystal size in crystals confined to CPG and p-PCHE. They found size-
dependent polymorphism and the potential for polymorph discovery with varying pore size, 
making particular note of the interplay between surface energy and volume free energy at 
the nanoscale. Three pore sizes of CPG and one size of p-PCHE monolith were studied.
This work aims to explore the crystallization of APIs in rigid nanoporous media over a 
broad range of pore sizes, which is lacking in existing studies, allowing a fundamental 
understanding of the relationship between pore size, crystallinity and bioavailability. The 
API fenofibrate (shown in Fig. 1), which is known in two polymorphic forms, was 
crystallized over a range of pore sizes (10 different pore sizes between 12 and 300 nm) of 
CPG. The drug loadings were determined with thermogravimetric analysis (TGA) and the 
nanocrystal melting points and enthalpies of fusion were studied with differential scanning 
calorimetry (DSC). Crystallinity was assessed with X-ray powder diffraction (XRPD), while 
both polymorphism and degree of crystallinity was studied using solid-state nuclear 
magnetic resonance (ssNMR). It is the intent that the porous matrices used be biocompatible 
excipient media, such that a formulation of the nanocrystalline API could conceivably be as 
simple as encapsulated API-loaded matrix.
2 Experimental section
2.1 Materials
Fenofibrate (FEN) was obtained from Xian Shunyi Bio-chemical Technology Company. 
Silicon dioxide (silica) particles of varying pore sizes were obtained from three sources. 
Controlled pore glass (CPG) was obtained from Millipore in pore sizes of 300 nm and 70 
nm. CPG was also obtained from Prime Synthesis in pore sizes of 191.4, 151.5, 105.5, 53.7, 
38.3, 30.7, 20.2, and 12.7 nm.
2.2 Experimental Apparatus
Experimental setup is shown in Fig. 2: (1) A small amount (∼ 0.25 g) of CPG was placed in 
a 20 mL scintillation vial, resulting in a CPG bed height of about 0.3 cm and a top surface 
area of ∼ 3.1 cm2. For this study, the preparation of 0.25 g of CPG to be loaded with drug 
was plenty for analytical purposes. (2) The pore volume present in the entire CPG sample 
was then calculated based on the given pore volume/gram CPG. A 60% weight/volume 
solution of fenofibrate in ethyl acetate was prepared. API solution in equal amount to the 
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pore volume present in the CPG was then micropipetted over the surface of the CPG in the 
scintillation vial as uniformly as possible. (3) Immediately after pipetting, a metal spatula 
was used to stir the mixture, to wet as much of the CPG as possible, ceasing only when the 
mixture appeared dry. The drug-loaded CPG was then left in a fume hood for an additional 
24 hrs to continue evaporation of excess solvent. It is noteworthy that no wash step was 
required in this method. Samples were prepared in triplicate for each pore size.
2.3 X-Ray Powder Diffraction Analysis
X-Ray powder diffraction (XRPD) was performed on all samples using a PANalytical 
X'Pert PRO diffractometer at 45 kV with an anode current of 40 mA. The instrument has a 
PW3050/60 standard resolution goniometer and a PW3373/10 Cu LFF DK241245 X-ray 
tube. Samples were placed on a spinner stage in reflection mode. Settings on the incident 
beam path included: soller slit 0.04 rad, mask fixed 10 mm, programmable divergence slit 
and fixed 1° anti-scatter slit. Settings on the diffracted beam path include: soller slit 0.04 rad 
and programmable anti-scatter slit. The scan was set as a continuous scan: 2θ angle between 
4 and 40 °, step size .0167113 ° and a time per step of 31.115 s.
2.4 Differential Scanning Calorimetry Analysis
A Q2000 instrument from TA instruments was utilized for the differential scanning 
calorimetry (DSC) analysis. Inert atmosphere environment was maintained in the sample 
chamber using a nitrogen gas cylinder set to a flow rate of 50 ml/min. An extra refrigerated 
cooling system (RCS 40, TA instruments) was used to broaden the available temperature 
range between 40 and 400 °C. Tzero ® pans and lids were used with ∼5 mg of sample. A 
heating rate of 10 °C/min was applied and the samples were scanned from -20 to 180 °C. 
When determining the enthalpy of fusion for a given sample, the DSC curve was integrated 
for 30 °C centered on the melting temperature of each pore size to capture the entire melting 
event.
2.5 Thermogravimetric Analysis
Thermogravimetric analysis (TGA) was performed on a Q500 instrument from TA 
instruments connected with a nitrogen gas cylinder to maintain a flow rate of 25 mL/min to 
keep the sample chamber under an inert gas environment. Between 5 and 10 mg of sample 
were loaded on platinum sample pans from TA instruments. The samples were allowed to 
equilibrate at 30 °C and then heated at 10 °C/min to 300 °C.
2.6 Solid-state Nuclear Magnetic Resonance Spectroscopy
Solid-state nuclear magnetic resonance experiments were conducted on a homebuilt 500 
MHz spectrometer (D. Ruben, Francis Bitter Magnet Laboratory (FBML), Massachusetts 
Institute of Technology). Prepared samples were packed into Revolution NMR (Fort Collins, 
USA) 4 mm o.d. (60 ul fill volume) ZrO2 rotors, equipped with Vespel drive and top caps. 
Spectra were acquired on a 4 mm Chemagnetics triple resonance (1H/13C/15N) magic-angle 
spinning (MAS) probe. 13C natural abundant spectra were acquired using cross-polarization 
(CP) [32], a recycle delay of 3 seconds, between 16,384 and 65,536 co-added transients and 
a spinning frequency of 9,000 ± 3 Hz. The Hartman-Hahn match condition was optimized 
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by setting 1H to 50 kHz (γB1/2π), a positive ramp contact pulse for 13C (centered at 58 kHz) 
and a contact time of 1.5 ms. All data were acquired using two-pulse phase-modulated, 
TPPM [33] 1H decoupling (100 kHz, 1H γB1/2π). The magic-angle was adjusted using 
potassium bromide (KBr) at a spinning frequency of 5 kHz, (rotational echoes > 11.5 
ms). 13C spectra were referenced (and shimmed, FWHM = 4 Hz) using solid adamantane to 
40.49 ppm (high frequency resonance) with respect to DSS (0 ppm).
2.7 Dissolution test
The dissolution tests were designed following USP standards. Analysis of the percentage of 
dissolved API was done using built-in ultraviolet-visible spectroscopy at 286 nm. The 
dissolution buffer used was .025 M sodium dodecyl sulfate solution (7.21 grams of 
powdered SDS (Sigma Aldrich) was dissolved and brought up to 1000 mL in water). The 
dissolution profile of the sample was determined using USP Dissolution Apparatus 2 at 37 
°C. The apparatus operated at 75 RPM. 900 mL of the buffer solution was allowed to reach 
the equilibrium temperature before sample was placed in the apparatus. Enough sample of 
API-loaded CPG was added such that the targeted concentration of fenofibrate in solution 
was 15 μg/mL, within the expected linear range [34]. Samples of both uncrushed and 
crushed bulk fenofibrate were analyzed as comparison. Samples were acquired for about 29 
hours.
3 Results and discussion
Fenofibrate was selected as a model API to work with in preliminary studies. It is poorly 
water soluble, < 1 mg/mL at 37 °C [35], and has two known polymorphs, crystalline form I 
with a melting point around 80 °C and a metastable form II with a melting point around 73 
°C [36] [37]. The metastable form has been collected in a sample of amorphous fenofibrate 
that was heated to around 40°C [36]. Fenofibrate was chosen for initial studies due to its 
lack of multiple stable polymorphs; it is advantageous to first study how a single polymorph 
changes with varying crystal size. Table 1 summarizes the sizes of CPG used and the pore 
volumes as provided by the supplier.
All loading data, melting points, and polymorph observations via XRPD and ssNMR are 
summarized in Table 2. High drug loadings were achieved via the method of applying the 
pore volume of drug solution. In the XRPD samples, there is a large amorphous feature 
which disrupts the baseline (to be subtracted) due to the amorphous silica matrix which 
makes up the bulk of the sample. NMR is isotope selective and invariant to the substrate that 
the API is placed upon offering an approach to probe the degree of crystallinity and identify 
polymorphs easily using 13C CP MAS NMR. Overall drug loading is reasonably well 
correlated to both pore volume and mean pore size but appears more closely dependent on 
the nominal pore size.
Fenofibrate in 20 to 300 nm CPG illustrated clean 13C spectra with high crystalline API 
formation. DSC and XRPD data indicated an inability to crystallize fenofibrate in the 12 nm 
CPG, suggesting an amorphous form (vide infra). In examining the literature, it has been 
reported that the pore diameter should be at least 20 times the molecular diameter for 
crystallization in confined spaces [38]. Fenofibrate has an estimated molecular size of 
Dwyer et al. Page 5









0.98-1.27 nm [34]. It is hypothesized that this is the reason why the 12 nm CPG showed no 
crystalline fenofibrate in the powder x-ray diffraction results, as it is less than 20 times the 
diameter of fenofibrate. Ha et al. found an similar size limit to crystalline versus amorphous 
stability in porous matrices, noting that crystallization of the compound ROY was supressed 
in 20 nm pores as compared to 30 nm pores when carried out either by evaporation or by 
melting/cooling [23]. We postulate that under slow crystallization conditions, crystals could 
be formed in pore sizes under 20 times the molecular diameter, which would explain the 
combination of broadened (i.e., amorphous phase) and narrow (i.e., crystalline) 13C 
resonance observed in the 12 nm sample (Supp. Info. Figure SIVa).
A major challenge in this work was to produce crystals which are successfully loaded in the 
porous matrix, rather than on the external surfaces. DSC was used to determine if surface 
crystals were present; in cases where both nanocrystals and surface crystals were formed, 
there are two obvious peaks present on the DSC scans corresponding to melting points of the 
confined crystals and the surface crystals (Supp. Info. Figure SII). Each trial was deemed 
successful in producing confined crystals with surface crystals when there was no 
measurable second peak on the DSC scans. This conclusion is supported by the work of 
O'Mahony et al., where SEM imaging of the surface of drug-loaded nanoporous substrate 
was used to confirm that crystals were confined to the pores and that no significant amount 
of bulk crystals were present on the surface of the substrate [39]. In this study, there was no 
occurrence of surface crystals that were nano-sized rather than bulk-sized.
3.1 Crystal form identification with XRPD
With the exception of fenofibrate in 12 nm CPG which showed no crystallinity, all samples 
showed the same XRPD peak pattern, both within trials of the same size CPG and across 
different sizes of CPG. Fig. 3 (a) is a scan of bulk fenofibrate and Fig. 3 (b) shows the 
XRPD scans of a single representative size of 53 nm CPG, across all three trials. It is evident 
that the crystal pattern is consistent throughout trials of a given pore size, which was also 
seen in all other pore sizes. Fig. 3 (c) shows an overlay of scans from three representative 
CPG sizes (191, 53, and 70 nm). Crystalline fenofibrate form I has reported theoretical 
diffractogram main peaks at 12° (2θ), 14.5° (2θ), 16.2° (2θ), 16.8° (2θ), and 22.4° (2θ) [36]. 
The identity of all samples of nanocrystalline fenofibrate as form I can be confirmed by 
matching peaks and the absence of other peak positions.
3.2 Crystal form identification with ssNMR
13C CP MAS NMR spectra for all fenofibrate loaded porous silica particles were used to 
identify amorphous or crystalline fenofibrate and identify whether the crystalline phase 
present were form I or II. All 13C MAS NMR spectra illustrate highly crystalline fenofibrate 
(form I), with line widths between 60 and 85 Hz (Supp. Info, Figures SIVa-i). Isotropic 
chemical shift data for silica particles with pore sizes ranging between 20 and 300 nm 
revealed identical spectra with no evidence of structural disorder. The slight decrease in 
resolution (13C line broadening from 300 to 20 nm) is due to the increase of surface disorder 
as the nanocrystals become increasingly smaller (i.e., surface vs nanocrystalline core).
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The 13C MAS NMR spectrum of the 12 nm CPG sample is slightly more complex; although 
the three well-resolved high frequency 13C resonances indicate form I of fenofibrate, all 13C 
resonances were broadened with the aromatic region being most affected (Supp. Info. Figure 
SIVa). We attribute this broadening to the small pore size causing a high degree of structural 
disorder, which often occurs when API's begin to form an amorphous phase or very small 
nanocrystalline formation. This observation agrees with the powder x-ray diffraction data 
which exhibits a single broad featureless lump, consistent with the lack of long-range 
periodic order. Finally, the poor fenofibrate loading on the 12 nm CPG pore size as 
determined by the TGA is reflected by a rather poor signal-to-noise after considerable 
averaging and comparable sample mass when ssNMR was performed on this material. The 
small pore size could retard the ability of fenofibrate to form nanocrystals as discussed 
above.
3.3 Analysis of melting point depression of nanocrystals by DSC
The melting point of bulk fenofibrate crystals was measured and found to be 81.6 ± 0.2 °C. 
Fig. 5 shows an overlay of the DSC scans for representative trials of fenofibrate crystallized 
in each CPG pore size. Individual, sharp peaks can be found at decreasing melting point 
temperatures, moving left as the CPG pore size decreases. Double peaks were not seen in the 
trials, indicating the preparation method was successful inhibiting the formation of any 
surface crystals.
It is well known that the Gibbs-Thomson equation can be used to describe the melting point 
depression seen in nanocrystals [40]. The complete Gibbs-Thomson equation for 
nanocrystals confined to pores is as follows:
Eq. 1
where Tm is the bulk melting temperature, Tm(d) is the melting temperature of a confined 
crystal with diameter d assumed equal to the pore diameter, M is the molecular mass, ρsolid 
is the density of the solid, γsolid–liquid is the surface free energy of the solid-liquid interface, 
ΔHfus is the molar enthalpy of fusion, and θ is the contact angle between the wall and 
crystal. If a standard contact angle of 180° is assumed, the equation reduces to
Eq. 2
At this point, it is evident that if the surface energy interaction term and the enthalpy of 
fusion, Hfus, remains constant, there is an expected linear relationship between the melting 
point and 1/d. Fig. 6 is the plot of 1/d for the fenofibrate in the given range of pore diameters 
versus the melting point temperature, taken from the DSC peaks. The data fits a linear trend. 
If the linear fit is extrapolated to 1/d = 0, it predicts the melting point of an infinite diameter 
particle which is the bulk melting point. The fit predicts a bulk melting point of 81.6 °C, 
equal to the measured bulk melting temperature of 81.6 °C.
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It is clear that the linear Gibbs-Thomson equation wherein the enthalpy of fusion and 
surface interaction energies are assumed constant accurately predicts the bulk melting 
temperature. However, the enthalpy of fusion was also measured in the DSC experiments, 
and was determined to be non-constant. It, too, can be plotted against 1/d, as seen in Fig. 7. 
It is shown to decrease linearly with 1/d.
In accordance with a study done by Ha et al. [22] the Young equation to describe the 
equilibrium contact angle allows the substitution of (γsolid–liquid cosθ) in the original Eq. 1 
with(γsolid–substrate – γliquid–substrate). This yields the modified equation:
Eq. 3
As nanocrystals size decreases, it is expected that the surface energy of the solid approaches 
that of its corresponding liquid. The difference term, (γsolid–substrate – γliquid–substrate), should 
therefore decrease and approach zero. The decrease in this term, found in the numerator, 
likely offsets the decrease in the enthalpy of fusion term found in the denominator. This 
would produce the apparent linear Gibbs-Thomson relationship reflected in the data despite 
the known change in enthalpy.
3.4 Enhanced dissolution profile for nanocrystalline fenofibrate
Dissolution profiles were tested and shown in Fig. 8. The nanocrystalline fenofibrate with 
the most enhanced dissolution profile occurred in the 70 nm CPG matrix, shown in detail in 
Fig. 9. These fenofibrate nanocrystals showed a roughly 7 fold increase in dissolution rate 
compared with crushed bulk fenofibrate. They reached >80% dissolution in 42.5 minutes 
where crushed bulk fenofibrate reached >80% dissolution in 295.5 minutes. Fenofibrate 
nanocrystals confined to 20 and 30 nm CPG had profiles which aligned closely with the 
crushed bulk profile indicating that, at small pore sizes, diffusional resistance likely matters 
to enhancing dissolution rate. Nanocrystals in CPG above 30 nm showed improved 
dissolution over the bulk crushed and uncrushed fenofibrate crystals at all time points of the 
study. The dissolution profiles can be clustered into two groups based on manufacturer. The 
70 nm and 300 nm (Millipore CPG) confined fenofibrate nanocrystals are the most enhanced 
profiles and show the expected faster dissolution with smaller pore/crystal size. The 
fenofibrate nanocrystals confined to the other pore sizes (Prime Synthesis CPG) all have 
very similar, still improved, dissolution profiles with no discernible trend by pore size. It is 
likely that the differences in pore geometry and tortuosity of the two types of CPG 
contribute to the differences in improvement in dissolution rate seen in the study.
4 Conclusion
We successfully obtained nanocrystalline fenofibrate over a broad range of sizes by using 
rigid matrices of porous silica. The results of the study indicate a decreasing melting point 
and enthalpy of fusion with decreasing pore size in nanocrystals. The decrease in the 
enthalpy of fusion is offset by a simultaneous decrease in the difference between the surface 
interaction of the solid-substrate and melt-substrate. This produces seemingly linear 
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behavior in melting point depression as predicted by the Gibbs-Thomson equation. The 
dissolution testing showed enhanced dissolution profiles for the nanocrystalline materials 
confined to different porous matrices, with fenofibrate confined in 70 nm CPG from 
Millipore showing the greatest improvement in dissolution. The controlled pore glass 
matrices used in this study are not currently accepted materials for oral drug delivery as they 
do not fulfil requirements of the European Pharmacopeia or the United States Pharmacopeia 
and the National Formulary; however, the ability to form nanocrystals across a range of pore 
sizes in this material suggests the potential to use drug-loaded rigid matrices of 
biocompatible materials to serve as an oral dosage forms with enhanced dissolution ability 
for poorly water soluble APIs.
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Fig. 1. Organic molecule of interest, fenofibrate (FEN) for API loading in porous silica used for 
this study
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Fig. 2. Loading procedure to impregnate porous silica particles with API solution
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Fig. 3. XRD patterns of bulk fenofibrate presented in (a), fenofibrate loaded on 53 nm CPG in 3 
distinct trials in (b), and fenofibrate loaded on three representative pore sizes of CPG in (c)
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Fig. 4. 13C CP MAS NMR spectra of fenofibrate: molecule (top), bulk drug (middle) and loaded 
in 20 CPG (bottom)
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Fig. 5. DSC scans of all CPG pore sizes showing single peaks (no surface crystals) with increasing 
melting point temperatures. Peaks are separated by color and correspond left to right to 
increasing pore sizes 20 to 300 nm
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Fig. 6. Constant enthalpy-constant surface interaction energy Gibbs-Thomson equation fit to 
melting points of fenofibrate nanocrystals confined to porous silica
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Fig. 7. Enthalpy of fusion of fenofibrate nanocrystals showing a linear relationship with 1/d 
across varying CPG pore sizes
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Fig. 8. Average dissolution profiles of all CPG-confined fenofibrate nanocrystals showing 
enhanced dissolution rates compared to crushed and uncrushed bulk fenofibrate, also shown
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Fig. 9. Comparison of the most enhanced dissolution profile of nanocrystalline fenofibrate in 70 
nm CPG compared to bulk crushed fenofibrate
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Table 1
Pore sizes, surface areas, and volumes of porous silica used in the study as provided by 
producer
Pore Size (nm) Pore Volume (cc/gram) Surface Area (m2/gram) Producer
300 1.21 10 Millipore
191.4 1.5 30 Prime Synthesis
151.5 1.2 31 Prime Synthesis
105.5 1.4 52 Prime Synthesis
70 1.22 43 Millipore
53.7 1.3 94 Prime Synthesis
38.3 1.3 138 Prime Synthesis
30.7 1.11 145 Prime Synthesis
20.2 1.12 219 Prime Synthesis
12.7 0.5 137 Prime Synthesis
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Table 2
Fenofibrate loaded in porous silica particles
Pore size (nm) FEN mass loaded (wt %) Melting point by DSC (°C) Polymorph by XRPD Polymorph by ssNMR
300 29.4±1.2 79.9±0.1 Form I Form I
191.4 40.0±2.0 79.8±0.5 Form I Form I
151.5 31.5±1.0 79.0±0.2 Form I Form I
105.5 35.7±0.5 78.7±0.2 Form I Form I
70 28.1±0.4 77.7±0.2 Form I Form I
53.7 33.4±0.4 75.2±0.6 Form I Form I
38.3 29.4±0.4 71.8±0.5 Form I Form I
30.7 29.4±0.7 71.2±0.1 Form I Form I
20.2 26.2±0.8 64.2±0.4 Form I Form I
12.7 16.3±0.6 N/A Amorphous Amorphous/Form I
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